TABLE 2.

Performance of SPACE2 on test datasets.

Dataset	Anti-lysozyme mAbs	CoV-AbDab (test)	EV	NVA1	NVA2
Antibodies in set	53	7,685	126	31	33
Fraction of antibodies modeled	1.0	1.0	0.87	1.0	1.0
Fraction of consistent clusters	1.0	0.85	0.78	0.83	1.0
Fraction of clustered antibodies in consistent clusters	1.0	0.80	0.74	0.86	1.0
Multiple-occupancy clusters	5	1,267	9	6	5
Antibodies in multiple-occupancy clusters	50 (94%)	4,188 (54%)	19 (15%)	14 (45%)	16 (48%)
Antibodies in consistent multiple-occupancy clusters	50 (94%)	3,353 (44%)	14 (11%)	12 (39%)	16 (48%)

Values of the five performance metrics and the fraction of antibodies successfully modeled using ABodyBuilder2 are shown for each dataset. For the two metrics of number of antibodies in multiple-occupancy clusters and number of antibodies in epitope-consistent multiple-occupancy clusters, a percentage is shown additionally, indicating the percentage of antibodies in the dataset. CoV-AbDab (test) denotes the subset of CoV-AbDab that is not contained in the Cao et al. (2023) training set (see Materials and Methods). CoV-AbDab (test) was used for this analysis to prevent testing on training set antibodies.